Ashok D. Nikapota
Brighton, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605].
Journal: European urology
Published: January 21, 2023
The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
Journal: European urology
Published: January 19, 2023
Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: November 17, 2022
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.
Journal: European urology
Published: November 19, 2021
Patient-Reported Outcomes and Health-Related Quality of Life Following Radiotherapy for Bladder Cancer.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: January 26, 2021
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 19, 2020
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 28, 2019
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 13, 2018
Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: November 05, 2017
Last Updated: 09/26/2026